Founded in 2007 in Winterthur, Switzerland, SIS (Swiss Interventional Systems) Medical AG is the inventor of the OPN NC – the Super-High-Pressure PTCA balloon. The company’s proprietary TWIN-Wall technology facilitates the manufacturing of high-performance interventional balloons, which can be inflated up to 35 atm. The special design with two balloon walls, perfectly aligned with each other, allows OPN NC to sustain this enormous pressure, without compromising the balloon compliance capabilities. The stable cylindrical shape of the OPN NC in combination with super high pressure makes this balloon a very useful and safe tool for the treatment of challenging lesions within the coronary vessel. This innovative product can be used either for pre-dilatation to prepare for stent placement or for post-dilatation to address stent under-expansion.
In addition to OPN NC, SIS Medical AG has developed a number of other products. The EasyT product line (not cleared in US) is a “work horse”, non-compliant balloon. The two NIC products (NIC Nano Hydro and NIC 1.1 Hydro, both products are not cleared in US) allow the user to enter very tiny lesions, with balloon diameters as small as 0.85mm, and are used in CTO (chronic total occlusion) cases and for dilatation of the marginal branches.
In October 2015, the SHS Investment Group, (www.shs-capital.eu) became the major shareholder of SIS Medical AG. SHS was founded in 1993 as an independent private equity company with the focus on investments in the MedTech and Life Sciences sector and is located in Tübingen, Germany. SHS with its vast experience in this field, has been investing in the development of SIS Medical AG and supporting its growth. As a first result of the SHS investment, SIS Medical AG moved in May 2016 to a new location with state-of-the-art facilities in Frauenfeld, Switzerland, establishing a base for further, successful expansion. This relocation enabled SIS Medical’s transformation from a young, promising Swiss company into a successful enterprise operating worldwide.
The US FDA clearance of the OPN NC in 2022 opened a large new market for SIS Medical AG and has made the innovative TWIN-Wall technology available to US patients.
Today, SIS Medical AG continues to develop and to innovate. Its cutting-edge manufacturing within a proprietary clean-room facility allows the company to keep all important production know-how in-house. The company is led by CEO Sergej Kammerzell, who succeeded the long-serving previous CEO and founder of SIS Medical AG, Willi Zwahlen, in 2020.
As of early 2023, the company has sharpened its MISSION and VISION statements and is well prepared for further expansion.
SIS Medical AG’s VISION is to become the leading, globally acting provider of high quality endovascular solutions. We strive to improve patients’ lives by making optimal lesion preparation a global standard of care.
SIS Medical AG’s MISSION: SIS Medical AG is a Swiss company, which develops, manufactures and distributes premium high-quality medical devices for endovascular lesion treatment. We drive value for our customers and patients by providing products, which achieve optimal therapeutic results.
Ever since its foundation, SIS Medical AG has been and will remain committed to the development, production and distribution of innovative high performance PTCA balloon catheters, designed to facilitate the daily work of cardiologists and to offer enhanced treatment options.
Our success story continues. You are kindly invited to follow us and become a part of it.
